Cargando…
A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplanation
This pilot study evaluates the degree of side effects during high-dose chemotherapy (HD-VIC) plus autologous bone marrow transplant (HDCT) and its possible prevention by the cytoprotective thiol-derivate amifostine. Additionally, the in-patient medical costs of both treatment arms were compared. 40...
Autores principales: | Hartmann, J T, Vangerow, A von, Fels, L M, Knop, S, Stolte, H, Kanz, L, Bokemeyer, C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363753/ https://www.ncbi.nlm.nih.gov/pubmed/11161394 http://dx.doi.org/10.1054/bjoc.2000.1611 |
Ejemplares similares
-
Autologous bone marrow transplanation for extramedullary plasmacytoma presenting as adrenal incidentaloma
por: Ahmed, Mohammed, et al.
Publicado: (2009) -
A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer
por: Johnson, P W M, et al.
Publicado: (2001) -
First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial
por: Bokemeyer, C, et al.
Publicado: (2003) -
Radioprotection of hematopoietic progenitors by low dose amifostine prophylaxis
por: Seed, Thomas M., et al.
Publicado: (2014) -
Old Vic saga /
por: Williams, Harcourt, 1880-1957
Publicado: (1949)